Hip joint mobility improved significantly in the treatment group compared with the placebo group (P 0.033). Similarly, pain decreased significantly in the treatment group compared with the placebo group (P 0.035). Two patients (4%) from each group withdrew during the early stages of the trial for reasons not related to treatment.